New drug aims to build muscle, fight rare genetic disease
NCT ID NCT05548556
Summary
This study is testing an investigational drug called RO7204239 to see if it can increase muscle volume and slow disease progression in adults with FSHD, a genetic muscle-wasting disorder. The trial will measure changes in muscle size using MRI scans and check the drug's safety. Participants are adults with FSHD who can walk without assistance.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asst Grande Ospedale Metropolitano Niguarda
Milan, Lombardy, 20162, Italy
-
Kennedy Krieger Institute
Baltimore, Maryland, 21205, United States
-
National Hospital for Neurology and Neurosurgery,
London, WC1N 3BG, United Kingdom
-
Policlinico Universitario Agostino Gemelli
Rome, Lazio, 00168, Italy
-
Regents of the University of Colorado
Aurora, Colorado, 80045, United States
-
Rigshospitalet
København Ø, 2100, Denmark
-
Royal Victoria Infirmary
Newcastle upon Tyne, NE1 4LP, United Kingdom
-
University of Irvine Medical Center (UCIMC)
Orange, California, 92868, United States
-
University of Kansas Medical Center
Fairway, Kansas, 66205, United States
-
Virginia Commonwealth University Medical Center
Richmond, Virginia, 23298-0599, United States
Conditions
Explore the condition pages connected to this study.